Skip to main content

Fenwick Represents Epitel in $26M Series B Round

EXPERIENCE Banner Image

Fenwick represented Epitel, a leader in AI-driven wireless brain health technologies, in its $26 million Series B funding. The round was co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors. More information can be obtained here.

The Fenwick transaction team was led by corporate partner Ryan Slunaker and included associates Tempestt Edward and Kale Olmstead.